中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.021 seconds)

    CYSTEINE ENGINEERED FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES
    1.
    发明申请
    CYSTEINE ENGINEERED FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES 有权

    公开(公告)号：US20210301025A1

    公开(公告)日：2021-09-30

    申请号：US17303425

    申请日：2021-05-28

    Applicant: Janssen Biotech, Inc.

    Inventor： Shalom GOLDBERG ,  Steven Jacobs ,  Tricia Lin ,  Karyn O'Neil

    IPC: C07K16/28 ,  G01N33/74 ,  C07K14/78

    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

    Cysteine engineered fibronectin type III domain binding molecules
    2.
    发明授权
    Cysteine engineered fibronectin type III domain binding molecules 有权

    公开(公告)号：US10196446B2

    公开(公告)日：2019-02-05

    申请号：US14512801

    申请日：2014-10-13

    Applicant: Janssen Biotech, Inc.

    Inventor： Shalom Goldberg ,  Steven Jacobs ,  Tricia Lin ,  Karyn O'Neil

    IPC: C07K16/28 ,  G01N33/74 ,  C07K14/78 ,  A61K39/00

    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

    Cysteine Engineered Fibronectin Type III Domain Binding Molecules
    3.
    发明申请
    Cysteine Engineered Fibronectin Type III Domain Binding Molecules 审中-公开
    半胱氨酸工程化纤连蛋白III型结构分子

    公开(公告)号：US20150104808A1

    公开(公告)日：2015-04-16

    申请号：US14512801

    申请日：2014-10-13

    Applicant: JANSSEN BIOTECH, INC.

    Inventor： Shalom Goldberg ,  Steven Jacobs ,  Tricia Lin

    IPC: C07K16/28 ,  G01N33/74 ,  C07K14/435

    CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K14/78 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2318/20 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31 ,  G01N33/74

    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

    Abstract translation: 通过诱变母体分子的核酸序列并用半胱氨酸代替一个或多个氨基酸残基来编码半胱氨酸来制备含有一个或多个游离半胱氨酸氨基酸的半胱氨酸改造的单特异性和双特异性EGFR和/或c-Met FN3结构域的分子， 设计的含有单特异性或双特异性分子的FN3结构域; 表达含有半胱氨酸的FN3结构域的分子; 并回收含有半胱氨酸的FN3结构域的分子。 分离的半胱氨酸改造的单特异性或双特异性FN3结构域含有的分子可以共价连接到检测标记或药物部分，并在治疗上使用。

    Cysteine engineered fibronectin type III domain binding molecules
    5.
    发明授权
    Cysteine engineered fibronectin type III domain binding molecules 有权

    公开(公告)号：US11072663B2

    公开(公告)日：2021-07-27

    申请号：US16227597

    申请日：2018-12-20

    Applicant: Janssen Biotech, Inc.

    Inventor： Shalom Goldberg ,  Steven Jacobs ,  Tricia Lin ,  Karyn O'Neil

    IPC: C07K16/28 ,  G01N33/74 ,  C07K14/78 ,  A61K39/00

    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Patent Agency Ranking